Literature DB >> 10836514

Involvement of tumor necrosis factor-alpha during infection of human monocytic cells by Toxoplasma gondii.

A Belloni1, D Aubert, J E Gomez Marin, R Le Naour, A Bonhomme, M Guenounou, J M Pinon.   

Abstract

Although the involvement of tumor necrosis factor-alpha (TNF-alpha) during Toxoplasma gondii infection has largely been described in mouse models, only a few studies in human models have been reported. We demonstrated the role of TNF-alpha during the process of invasion by T. gondii in human monocytic cells. Cotreatment of cells with interferon-gamma (IFN-gamma) and lipolysaccharide (LPS) during T. gondii infection induced TNF-alpha production and decreased the number of parasitized cells (invasion index). Neutralization of the production of TNF-alpha using a specific monoclonal antibody or pentoxifylline enhanced the invasion index. The relationship between TNF-alpha production and protection of monocytic cells against T. gondii invasion was confirmed by treatment of infected cultures with exogenous TNF-alpha. Thus, in contrast to the results obtained in murine models but in accordance with those observed in other human models, the present study shows for the first time in human monocytic cells that T. gondii does not induce any TNF-alpha secretion and inhibits TNF-alpha production induced by IFN-gamma/LPS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836514     DOI: 10.1007/s004360050685

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  2 in total

1.  Suppressed production of pro-inflammatory cytokines by LPS-activated macrophages after treatment with Toxoplasma gondii lysate.

Authors:  Eun-Jung Lee; Yoo-Mi Heo; Jong-Hak Choi; Hyun-Ouk Song; Jae-Sook Ryu; Myoung-Hee Ahn
Journal:  Korean J Parasitol       Date:  2008-09       Impact factor: 1.341

2.  First description of enhanced expression of glia maturation factor-beta in experimental toxoplasmic encephalitis.

Authors:  Gungor Cagdas Dincel
Journal:  J Int Med Res       Date:  2017-08-04       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.